Viewing data from:

DIFLORASONE DIACETATE

ANDA

DIFLORASONE DIACETATE | A075187 | AVONDALE PHARMACEUTICALS LLC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Diflorasone Diacetate (2023)

Total Spending

$15.1M

Total Claims

19,057

Beneficiaries

6,653

Avg Cost/Unit

$9.43

Spending Trend

$16.8M(2019)→$36.4M(2020)→$16.5M(2021)→$19.3M(2022)→$15.1M(2023)

YoY Change:-1.9%

5yr CAGR:-1.4%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain2 active DMFs1 inactive

2 active API suppliers hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

TAPI NL BVDIFLORASONE DIACETATE BULK DRUG

DMF 126071997

TARO PHARMACEUTICAL INDUSTRIES LTDDIFLORASONE DIACETATE USP MICRONIZED

DMF 158622002

PHARMACIA AND UPJOHNInactiveDIFLORASONE DIACETATE

DMF 57871985

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 0.05%

0 patents0 exclusivities▴

CREAM;TOPICAL | Approved: Mar 30, 1998

No patent or exclusivity listings for this strength.